| Systematic versus on-demand early palliative care: results from a multicentre, randomised clinical trial M Maltoni, E Scarpi, M Dall'Agata, V Zagonel, R Bertè, D Ferrari, ... European Journal of Cancer 65, 61-68, 2016 | 176 | 2016 |
| Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers? G Marisi, A Cucchetti, P Ulivi, M Canale, G Cabibbo, L Solaini, FG Foschi, ... World journal of gastroenterology 24 (36), 4152, 2018 | 171 | 2018 |
| In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of caspase-3–mediated apoptosis F Fornari, D Pollutri, C Patrizi, T La Bella, S Marinelli, A Casadei Gardini, ... Clinical cancer research 23 (14), 3953-3965, 2017 | 162 | 2017 |
| Systematic versus on-demand early palliative care: a randomised clinical trial assessing quality of care and treatment aggressiveness near the end of life M Maltoni, E Scarpi, M Dall’Agata, S Schiavon, C Biasini, C Codecà, ... European Journal of Cancer 69, 110-118, 2016 | 157 | 2016 |
| Aberrant metabolism in hepatocellular carcinoma provides diagnostic and therapeutic opportunities S De Matteis, A Ragusa, G Marisi, S De Domenico, A Casadei Gardini, ... Oxidative medicine and cellular longevity 2018 (1), 7512159, 2018 | 135 | 2018 |
| BRAF-mutated colorectal cancer: clinical and molecular insights F Caputo, C Santini, C Bardasi, K Cerma, A Casadei-Gardini, ... International journal of molecular sciences 20 (21), 5369, 2019 | 126 | 2019 |
| Patients with advanced hepatocellular carcinoma need a personalized management: a lesson from clinical practice EG Giannini, L Bucci, F Garuti, M Brunacci, B Lenzi, M Valente, E Caturelli, ... Hepatology 67 (5), 1784-1796, 2018 | 113 | 2018 |
| Immunotherapy for colorectal cancer: where are we heading? D Basile, SK Garattini, M Bonotto, E Ongaro, M Casagrande, M Cattaneo, ... Expert opinion on biological therapy 17 (6), 709-721, 2017 | 107 | 2017 |
| Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib AC Gardini, E Scarpi, L Faloppi, M Scartozzi, N Silvestris, D Santini, ... Oncotarget 7 (41), 67142, 2016 | 103 | 2016 |
| Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale AC Gardini, L Faloppi, S De Matteis, FG Foschi, N Silvestris, F Tovoli, ... European Journal of Cancer 86, 106-114, 2017 | 95 | 2017 |
| Shifts of faecal microbiota during sporadic colorectal carcinogenesis G Mori, S Rampelli, BS Orena, C Rengucci, G De Maio, G Barbieri, ... Scientific reports 8 (1), 1-11, 2018 | 86 | 2018 |
| Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis M Rimini, L Rimassa, K Ueshima, V Burgio, S Shigeo, T Tada, G Suda, ... ESMO open 7 (6), 100591, 2022 | 78 | 2022 |
| Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib A Casadei Gardini, G Marisi, E Scarpi, M Scartozzi, L Faloppi, N Silvestris, ... Expert opinion on pharmacotherapy 16 (18), 2719-2725, 2015 | 74 | 2015 |
| Predictive and prognostic factors in HCC patients treated with sorafenib O Brunetti, A Gnoni, A Licchetta, V Longo, A Calabrese, A Argentiero, ... Medicina 55 (10), 707, 2019 | 73 | 2019 |
| Management of adverse events with tailored sorafenib dosing prolongs survival of hepatocellular carcinoma patients F Tovoli, L Ielasi, A Casadei-Gardini, A Granito, FG Foschi, G Rovesti, ... Journal of hepatology 71 (6), 1175-1183, 2019 | 72 | 2019 |
| NMR-based metabolomic approach tracks potential serum biomarkers of disease progression in patients with type 2 diabetes mellitus L Del Coco, D Vergara, S De Matteis, E Mensà, J Sabbatinelli, ... Journal of clinical medicine 8 (5), 720, 2019 | 67 | 2019 |
| Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population A Casadei-Gardini, M Rimini, T Tada, G Suda, S Shimose, M Kudo, ... European Journal of Cancer 180, 9-20, 2023 | 64 | 2023 |
| Immunotherapeutic approaches for hepatocellular carcinoma V Longo, A Gnoni, AC Gardini, S Pisconti, A Licchetta, M Scartozzi, ... Oncotarget 8 (20), 33897, 2017 | 64 | 2017 |
| Lactate dehydrogenase in hepatocellular carcinoma: something old, something new L Faloppi, M Bianconi, R Memeo, A Casadei Gardini, R Giampieri, ... BioMed research international 2016 (1), 7196280, 2016 | 64 | 2016 |
| KRAS, BRAF and PIK3CA Status in Squamous Cell Anal Carcinoma (SCAC) A Casadei Gardini, L Capelli, P Ulivi, M Giannini, E Freier, S Tamberi, ... PLoS One 9 (3), e92071, 2014 | 64 | 2014 |
Mario ScartozziUniversity of Cagliari, Italy在 unica.it 的电子邮件经过验证
